Hunter Associates Investment Management LLC Grows Holdings in Trinity Biotech plc (NASDAQ:TRIB)

Hunter Associates Investment Management LLC increased its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 378,590 shares of the company’s stock after buying an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Trinity Biotech in a research note on Wednesday. They set a “hold” rating on the stock.

Trinity Biotech Stock Performance

Shares of Trinity Biotech stock opened at $0.90 on Friday. The firm’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $1.59. Trinity Biotech plc has a 1 year low of $0.74 and a 1 year high of $3.55.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.